Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure

British Journal of Ophthalmology

Volumn 88, Issue 1, 2004, Pages 88-94

  Aung, T ^a   Oen, F T S ^a   Wong, H T ^b   Chan, Y H ^c   Khoo, B K ^b   Liu, Y P ^c   Ho, C L ^a   See, J ^a   Thean, L H ^d   Viswanathan, A C ^e   Seah, S K L ^a   Chew, P T K ^a,d,f  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c Clin Trials and Epidemiol Res U   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e MOORFIELDS EYE HOSPITAL   (United Kingdom)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; TIMOLOL; TIMOLOL MALEATE;

ADULT; AGE; AGED; ARTICLE; CHEMOSIS; CHINESE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; FEMALE; FIRST AID; HUMAN; INTRAOCULAR PRESSURE; IRIDOTOMY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERIMETRY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYMPTOM; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

ACUTE DISEASE; ADRENERGIC ALPHA-AGONISTS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; FEMALE; GLAUCOMA, ANGLE-CLOSURE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PERIMETRY; PROSPECTIVE STUDIES; QUINOXALINES; TIMOLOL; VISUAL FIELDS;

EID: 9144241000     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.88.1.88     Document Type: Article

References (39)

1. Seah SK, Foster PJ, Chew PT, et al. Incidence of acute primary angle closure glaucoma in Singapore: an island wide survey. Arch Ophthalmol 1997;115:1437-40.
2. Hoskins HD Jr, Kass MA. Becker-Shaffer's diagnosis and therapy of the glaucomas: angle-closure glaucoma with pupillary block. St Louis: CV Mosby, 1989:208-37.
3. Aung T, Ang LP, Chan SP, et al. Acute primary angle-closure: long-term intraocular pressure outcome in Asian eyes. Am J Ophthalmol 2001;131:7-12.
4. Douglas GR, Drance SM, Schulzer M. The visual field and nerve head in angle-closure glaucoma. A comparison of the effects of acute and chronic angle closure. Arch Ophthalmol 1975;93:409-11.
5. Dhillon B, Chew PT, Lim ASM. Field loss in primary angle-closure glaucoma. Asia-Pacific J Ophthalmol 1990;2:85-7.
6. Lowe RF. Primary angle-closure glaucoma: a review 5 years after bilateral surgery. Br J Ophthalmol 1973;57:457-63.
7. Bonomi L, Marraffa M, Marchini G, et al. Perimetric defects after a single acute angle-closure glaucoma attack. Graefes Arch Clin Exp Ophthalmol 1999;237:908-14.
8. Aung T, Looi AL, Chew PT. The visual field following acute primary angle closure. Acta Ophthalmol Scand 2001;79:298-300.
9. Wong JS, Chew PTK, Alsagoff A, et al. Clinical course and outcome of primary acute angle closure glaucoma in Singapore. Singapore Med J 1997;38:16-18.
10. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humour dynamics. Arch Ophthalmol 1995;113:1514-7.
11. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999;40:65-73.
12. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1999;9(Suppl 1):S17-21.
13. Vidal-Sanz M, Lafuente MP, Mayor S, et al. Retinal ganglion cell death induced by retinal ischemia: neuroprotective effects of two alpha-2 agonists. Surv Ophthalmol 2001;45(Suppl 3):S261-7.
14. Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol 2001;11(Suppl 2):S30-5.
15. WoldeMussie E, Ruiz G, Wijono M, et al. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-55.
16. Barneby H, for the Brimonidine Study Group. Long term efficacy of brimonidine on IOP lowering. Invest Ophthalmol Vis Sci 1996;37:S1102.
17. Lynch DR, Dawson TM. Secondary mechanisms in neuronal damage. Curr Opin Neural 1994;7:175-86.
18. Machin D, Campbell MJ, Fayers PM, et al. Sample size tables for clinical studies, 2nd ed. Oxford: Blackwell, 1997.
19. AGIS investigators. Advanced Glaucoma Intervention Study 2. Visual field test scoring and reliability. Ophthalmology 1994;101:1445-55.
20. Musch DC, Lichter PR, Guire KE, et al. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 1999;106:653-62.
21. Fitzke FW, Hitchings RA, Poinoosawmy D, et al. Analysis of visual field progression in glaucoma. Br J Ophthalmol 1996;80:40-8.
22. McNaught AI, Crabb DP, Fitzke FW, et al. Modelling series of visual fields to detect progression in normal-tension glaucoma. Graefes Arch Clin Exp Ophthalmol 1995;233:750-5.
23. Chauhan BC, Drance SM, Douglas GR. The use of visual field indices in detecting changes in the visual field in glaucoma. Invest Ophthalmol Vis Sci 1990;31:512-20.
24. Katz J, Gilbert D, Quigley HA, et al. Estimating progression of visual field loss in glaucoma. Ophthalmology 1997;104:1017-25.
25. Nouri-Mahdavi K, Brigatti L, Weitzman M, et al. Comparison of methods to detect visual field progression in glaucoma. Ophthalmology 1997;104:1228-36.
26. O'Brien C, Schwortz B. The visual field in chronic open angle glaucoma: the rate of change in different regions of the field. Eye 1990;4:557-62.
27. Wild JM, Hutchings N, Hussey MK, et al. Pointwise univariate linear regression of perimetric sensitivity against follow-up time in glaucoma. Ophthalmology 1997;104:808-15.
28. Spry PGD, Johnson CA. Identification of progressive glaucomatous visual field loss. Surv Ophthalmol 2002;47:158-73.
29. Spry PGD, Bates AB, Johnson CA, et al. Simulation of longitudinal threshold visual field data. Invest Ophthalmol Vis Sci 2000;41:2192-200.
30. Noureddin BN, Poinoosawmy D, Fitzke FW, et al. Regression analysis of visual field progression in low tension glaucoma. Br J Ophthalmol 1991;75:493-5.
31. Birch MK, Wishart PK, Odonnell NP. Determining progressive visual field loss in serial Humphrey visual fields. Ophthalmology 1995;102:1227-34.
32. Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Invest Ophthalmol Vis Sci 1996;37:1419-28.
33. Viswanathan AC, Fitzke FW, Hitchings RA. Early detection of visual field progression in glaucoma: a comparison of Progressor and Statpac 2. Br J Ophthalmol 1997;81:1037-42.
34. Viswanathan AC, Hitchings RA, Fitzke FW. How often do patients need visual field tests? Graefes Arch Clin Exp Ophthalmol 1997;235:563-8.
35. Anderson DR, Davis EB. Sensitivities of ocular tissues to acute-pressure induced ischemia. Arch Ophthalmol 1975;93:267-74.
36. Hillman JS. Acute closed-angle glaucoma: on investigation into the effect of delay in treatment. Br J Ophthalmol 1979;63:817-21.
37. Ingram RM, Ennis JR. Acute glaucoma: results of treatment by bilateral simultaneous iridectomy, now without admission to hospital. Br J Ophthalmol 1983;67:367-71.
38. McNauqht EI, Rennie A, McClure E, et al. Pattern of visual damage after acute angle closure glaucoma. Trans Ophthalmol Soc UK 1974;94:406-15.
39. Lowe RF. Clinical types of primary angle closure glaucoma. Aust NZ J Ophthalmol 1988;16:245-50.